Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis
Corresponding Author
Koichi Yanaba
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Correspondence: Koichi Yanaba, M.D., Ph.D., Department of Dermatology, Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-ku, Tokyo 105-8461, Japan. Email: [email protected]Search for more papers by this authorYoshinori Umezawa
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorHiromi Honda
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorReiko Sato
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorMiki Chiba
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorSota Kikuchi
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorAkihiko Asahina
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorHidemi Nakagawa
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Koichi Yanaba
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Correspondence: Koichi Yanaba, M.D., Ph.D., Department of Dermatology, Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-ku, Tokyo 105-8461, Japan. Email: [email protected]Search for more papers by this authorYoshinori Umezawa
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorHiromi Honda
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorReiko Sato
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorMiki Chiba
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorSota Kikuchi
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorAkihiko Asahina
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this authorHidemi Nakagawa
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
Search for more papers by this author
References
- 1Bardazzi F, Odorici G, Virdi A et al. Autoantibodies in psoriatic patients treated with anti-TNF-a therapy. J Dtsch Dermatol Ges 2014; 12: 401–406.
- 2Poulalhon N, Begon E, Lebbe C et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 2007; 156: 329–336.
- 3Hoffmann JH, Hartmann M, Enk AH et al. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol 2011; 165: 1355–1358.
- 4Pink AE, Fonia A, Allen MH et al. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-a therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010; 162: 780–785.
- 5Saraceno R, Specchio F, Torres T et al. The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-a agents: a retrospective long-term study. J Am Acad Dermatol 2012; 66: e180–e182.
Citing Literature
